Byron C. Hann, MD, PhD

Associate Researcher, Manager of Preclinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center

byron.hann@ucsf.edu

Phone: (415) 476-0419 (voice)
Box 0128, UCSF
San Francisco, CA 94143-0128

View on UCSF Profiles

Education

Reed College, Portland, Oregon, B.A., 1984, Physics
University of California, San Francisco, CA, Medical Scientist’s Training Program
University of California, San Francisco, CA, Ph.D., 1992, Biochemistry and Biophysics
University of California, San Francisco, CA, M.D., 1994, School of Medicine

Professional Experience

• 1983-1984
  Undergraduate: Senior Thesis, Physics, Chemistry Department, Reed College, "UV Spectroscopy of Wursters Blue; A Test of Huckel MO Theory". Advisors; Drs. Rich Bettega, Dennis Hoffman
• 1984
  Research Assistant, Laboratory of Dr. Steve Arch, Reed College Dept. of Biology. Analysis of neuropeptides released by bag cells of Aplysia californica.
• 1984-1985
  Post Graduate Research Physiologist, Laboratory of Dr. Louis Reichardt, UCSF School of Medicine, Dept of Physiology, Division of Neuroscience. Purification, characterization and cloning of a laminin binding protein.
• 1988-1992
  Ph.D. candidate, Laboratory of Dr. Peter Walter, UCSF School of Medicine, Dept. of Biochemistry and Biophysics. Identification and analysis of the signal recognition particle in Saccharomyces cerevisiae.
• 1994-1997
  Post-doctoral fellow, Laboratory of Prof. David Lane, CRC Labs, Department of Biochemistry, University of Dundee, Scotland. Phospho-regulation of p53: Identification of novel sites of p53 phosphorylation, generation of phospho-peptide antibodies, characterization of ATM, ATR phosphorylation of p53 in collaboration with S. Jackson Lab (Cambridge, England).
• 1997-1999
  Associate Scientist, Onyx Pharmaceuticals, Richmond, CA, Viral therapy and Cell Cycle groups. Analysis of the mechanism of action and selectivity of an onco-lytic, E1B 55-K deficient adenovirus (ONYX-015).
• 1999-2004
  Specialist, Laboratory of Dr. Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco CA. The role of p53 in regulating viral and cellular processes in primary and tumor human cells infected with E1B 55-K deficient adenoviruses. p53 dependent abrogation of 55-K deficient virus replication.
• 2004-present
  Associate Researcher, Director of UCSF Preclinical Core. Working closely with UCSF Breast and Prostate SPORE programs, RTK U54 program, and Pancreas Cancer Research Group to develop new animal models for preclinical studies and to oversee preclinical trials testing novel experimental therapeutics, diagnostics and imaging strategies.

Honors & Awards

• 1984
  
• Phi Beta Kappa
  
• President's Award for Excellence in Scholarship, Reed College, Portland, OR

Selected Publications

1. Lebeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, Vanbrocklin HF, Craik CS. Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer. Cancer Res. 2013 Apr 1; 73(7):2070-81.
   View on PubMed
2. Lebeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, Vanbrocklin HF, Craik CS. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A. 2013 Jan 2; 110(1):93-8.
   View on PubMed
3. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M. A central role for RAF?MEK?ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012 Aug; 2(8):685-93.
   View on PubMed
4. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH. TGFß1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 2011 Nov 1; 17(21):6754-65.
   View on PubMed
5. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012 Jan 26; 31(4):419-31.
   View on PubMed
6. Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl). 2011 Sep; 89(9):877-89.
   View on PubMed
7. Chen L, Hann B, Wu L. Experimental models to study lymphatic and blood vascular metastasis. J Surg Oncol. 2011 May 1; 103(6):475-83.
   View on PubMed
8. Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TßRI/II kinase inhibition with LY2109761. Cancer Res. 2011 Mar 15; 71(6):2339-49.
   View on PubMed
9. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer Res. 2010 Feb 15; 70(4):1505-12.
   View on PubMed
10. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7.
    View on PubMed
11. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 4; 141(1):13-21.
    View on PubMed
12. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9.
    View on PubMed
13. Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, Hann B, Diamond MI. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A. 2009 Apr 28; 106(17):7233-8.
    View on PubMed
14. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009 Apr 3; 137(1):87-98.
    View on PubMed
15. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 1; 15(7):2311-22.
    View on PubMed
16. Bouchard LS, Anwar MS, Liu GL, Hann B, Xie ZH, Gray JW, Wang X, Pines A, Chen FF. Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. Proc Natl Acad Sci U S A. 2009 Mar 17; 106(11):4085-9.
    View on PubMed
17. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008 Sep; 8(9):2851-7.
    View on PubMed
18. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25.
    View on PubMed
19. Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol. 2007 Jun; 71(6):1525-34.
    View on PubMed
20. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25; 445(7126):437-41.
    View on PubMed

View on UCSF Profiles